98%
921
2 minutes
20
Multiple myeloma (MM)-induced bone disease affects not only patients' quality of life but also their overall survival. Our previous work demonstrated that the gut microbiome plays a crucial role in MM progression and drug resistance. However, the role of altered gut microbiota in MM bone disease remains unclear. In this study, we show that intestinal Enterobacter cloacae is significantly enriched in patients with MM with osteolysis. Through fecal microbial transplantation and single bacterial colonization experiments in a 5TGM1 MM mouse model, we found that intestinal colonization of E cloacae promotes osteolysis by increasing circulating ammonium levels. Elevated ammonium promotes osteoclastogenesis by increasing Trap protein levels in osteoclast precursors and by acetylating and stabilizing chemokine ligand 3 protein in MM cells. Inhibition of ammonium synthesis, using E cloacae with a deleted dcd gene, along with probiotic supplementation, alleviated osteolysis in MM. Overall, our work suggests that E cloacae promotes osteolysis in MM by synthesizing ammonium. This establishes a novel mechanism and potential intervention strategy for managing MM with osteolysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1182/blood.2024025694 | DOI Listing |
J Microbiol Immunol Infect
August 2025
Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, And College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address:
Background: Third-generation cephalosporin-resistant Enterobacterales is a recognized global concern. This study investigated the molecular epidemiology of β-lactamase genes and antimicrobial susceptibility patterns among ceftriaxone-resistant Enterobacterales causing intra-abdominal and urinary tract infections in Taiwan between 2009 and 2019.
Methods: Data from the SMART surveillance program were analyzed, including Enterobacterales isolates with ceftriaxone minimum inhibitory concentrations ≥4 μg/mL.
PLoS One
September 2025
Faculty of Health, Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research (ZBAF), School of Medicine, Witten/Herdecke University, Witten, Germany.
The emergence of antibiotic resistance continues to pose a significant global challenge. Drug repurposing, wherein existing therapeutics are evaluated for new applications, offers a promising strategy to address this issue. Farnesyltransferase inhibitors (FTIs), initially developed for cancer therapy, have demonstrated antimicrobial activity against several gram-positive bacteria.
View Article and Find Full Text PDFFolia Microbiol (Praha)
September 2025
Department of Biotechnology and Genetic Engineering, Hazara University, Mansehra, Pakistan.
Herein, we report the isolation and characterization of an endophytic bacterium associated with the Berberis aristata roots to uncover bioactive compounds, particularly Antimicrobials, using submerged culture. The bacterial isolate was identified via 16S rDNA sequence analysis and characterized using morphological, microscopic, and biochemical techniques. It was identified as Bacillus toyonensis strain BAR1, a motile, gram-positive, halotolerant bacterium capable of producing yellow pigments.
View Article and Find Full Text PDFJ Glob Antimicrob Resist
September 2025
Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Electronic address:
Background: Metallo-β-lactamase (MBL)-producing Enterobacter cloacae complex (ECC) is an emerging threat associated with limited treatment options and increased mortality. This study aimed to describe the clinical and molecular characteristics, risk factors, and outcomes of MBL-producing ECC infections in Taiwan.
Methods: We conducted a retrospective cohort study at a tertiary hospital in central Taiwan from July 2022 to December 2023.
Cureus
August 2025
Medical Mycology Research Center, Chiba University, Chiba, JPN.
species are known to cause disseminated infections in immunocompromised hosts, typically in patients with hematological malignancies undergoing chemotherapy and those with a history of antifungal use. This case report described a non-neutropenic 85-year-old male patient with fungemia following polymicrobial bacteremia. He presented with fever and disturbed consciousness and was admitted for sepsis (day 1).
View Article and Find Full Text PDF